<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04234373</url>
  </required_header>
  <id_info>
    <org_study_id>LCP Obese</org_study_id>
    <nct_id>NCT04234373</nct_id>
  </id_info>
  <brief_title>Effect of a Low-carb Dietary Intervention in Obese Patients: a Pilot Trial</brief_title>
  <official_title>Understanding Gut-brain Interactions and the Effect of a Low-carb Dietary Intervention in Obese Patients With and Without Glucose Intolerance or Diabetes: a Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effects of a 6 months low-carb dietary intervention on glycemic control, body composition and
      gut-brain interaction in obese and lean patients with and without glucose intolerance or
      diabetes
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of a low-carb dietary intervention on glycemic control as defined by blood glucose level at 2h after an oral glucose tolerance test.</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of a low-carb dietary intervention on body composition as measured with dual-energy x-ray absorptiometry</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of a low-carb dietary intervention on metabolomics as measured in plasma, urine and stool samples</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>Metabolomic analysis of the bacterial metabolites present in the urine by combining nuclear magnetic resonance (1H-NMR) and mass spectrometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of a low-carb dietary intervention on gut microbiota composition as measured in stool samples</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>Human gut microbiota composition measured with metagenomic shotgun sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of a low-carb dietary Intervention on brain network activity as measured with functional MRI</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of a low-carb dietary intervention on liver fat fraction as measured with MRI</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Glucose Intolerance</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Low Carb dietary Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low Carb diet</intervention_name>
    <description>Low Carb diet (max. 130g carbohydrates/d) for 6 months</description>
    <arm_group_label>Low Carb dietary Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Group A: HEALTHY LEAN CONTROLS

          -  Healthy normal weight subjects with a body-mass index of 19.0-24.9kg/m2, HbA1C &lt;5.7%
             and fasting glucose &lt;5.6 mmol/l

          -  Normal eating habits

          -  Stable body weight for at least three months

          -  Informed Consent as documented by signature

        Group B: PRE-DIABETIC or DIABETIC OBESE

          -  Pre-diabetic/Diabetic obese with a HbA1C &gt;5.7% and/or fasting glucose &gt;5.6 mmol/l) and
             body-mass index &gt; 30kg/m2, otherwise healthy

          -  Normal eating habits

          -  Stable body weight for at least three months

          -  Informed Consent as documented by signature

        Exclusion Criteria:

        Group A: HEALTHY LEAN CONTROLS

          -  Pre-existing low carb diet (less than 45% of daily energy intake by carbohydrates)

          -  Pre-existing diet (vegetarian, vegan, gluten-free etc.)

          -  Psychiatric illness

          -  Alcohol abuse, (smoking allowed)

          -  Regular intake of medications, (oral contraceptives allowed)

          -  Intake of antibiotics within the last 3 months before inclusion

          -  Regular intake of pro- or prebiotics

          -  Chronic diseases of the gastrointestinal tract, history of gastrointestinal surgery
             with major changes to the gastrointestinal tract (e.g. bariatric surgery)

          -  Clinically relevant acute or chronic inflammatory disease

          -  Pregnancy

          -  Participation in another study with investigational drug within the 30 days preceding
             and during the present study.

        Group B: PRE-DIABETIC or DIABETIC OBESE

          -  Pre-existing low carb diet (less than 45% of daily energy intake by carbohydrates)

          -  Pre-existing diet (vegetarian, vegan, gluten-free etc.)

          -  Psychiatric illness

          -  Alcohol abuse, (smoking allowed)

          -  Regular intake of medications (except: oral contraceptives, metformin, SGLT-2,
             statins, and antihypertensive, which are allowed)

          -  Intake of antibiotics within the last 3 months before inclusion

          -  Regular intake of pro- or prebiotics

          -  Chronic diseases of the gastrointestinal tract, history of gastrointestinal surgery
             with major changes to the gastrointestinal tract (e.g. bariatric surgery)

          -  Clinically relevant acute or chronic inflammatory disease

          -  Pregnancy

          -  Participation in another study with investigational drug within the 30 days preceding
             and during the present study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bettina Wölnerhanssen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bettina Wölnerhanssen, MD</last_name>
    <phone>0041616858585</phone>
    <email>bettina.woelnerhanssen@unibas.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Christin Meyer-Gerspach, MSc, PhD</last_name>
    <phone>0041616858585</phone>
    <email>annechristin.meyergerspach@unibas.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Clara Research Ltd, St Claraspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4002</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bettina Wölnerhanssen, MD</last_name>
      <phone>0616858585</phone>
      <email>forschung@claraspital.ch</email>
    </contact>
    <contact_backup>
      <last_name>Valentine Bordier, MSc</last_name>
      <phone>0616858585</phone>
      <email>valentine.bordier@clarspital.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 21, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

